Royalty Report: Drugs, cardiac, Disease – Collection: 362449

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • cardiac
  • Disease
  • Therapeutic
  • Biotechnology
  • Drug Discovery
  • Proteins
  • Diagnostic
  • Alzheimer’s disease
  • Diabetes Treatment
  • obesity
  • Pharmaceuticals
  • Medical
  • Device

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 362449

License Grant
University hereby grants to Corporation and Corporation hereby accepts from University the License. License shall mean the exclusive worldwide license to practice the University Patents (as hereinafter defined) for the development, manufacture, use and sale of the Licensed Products (as hereinafter defined) in the Field.

University reserves the right to use, and to permit other non-profit academic institutions to use, the University Patents for educational and research purposes.

The parties acknowledge that the United States government retains rights in intellectual property funded under any grant or similar contract with a Federal agency. The License is expressly subject to all applicable United States government rights, including, but not limited to, any applicable requirement that products, which result from such intellectual property and are sold in the United States, must be substantially manufactured in the United, States.

Corporation shall be entitled to grant sublicenses under the License on terms and conditions in compliance and not inconsistent with the terms and conditions of this Agreement

License Property
University Scientists have made certain inventions relating to microRNA 33, metabolic disorders, and atherosclerosis, all as more particularly described in U.S. patent applications US provisional patent application number 61/377,789, filed August 27, 2010, and US provisional patent application number 61/412,720, filed November 11, 2010, both titled 'mir33 Inhibitors and Uses Thereof to Raise Plasma High Density Lipoprotein” owned by University (hereinafter the Pre-Existing Patent Applications).
Field of Use
Field shall mean the prophylactic or therapeutic reduction of microRNA 33 levels or activity for the treatment or prevention of metabolic disorders or atherosclerotic plaque in humans.

The patent rights encompassing the use of an anti-miR therapeutic targeting miR-33 for the treatment of atherosclerosis, metabolic syndrome and elevated triglycerides.
Atherosclerosis is the buildup of fats, cholesterol and other substances in and on your artery walls.
Metabolic syndrome is a cluster of conditions that occur together, increasing your risk of heart disease, stroke and type 2 diabetes. Metabolic syndrome includes high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels. The syndrome increases a person's risk for heart attack and stroke.
Aside from a large waist circumference, most of the disorders associated with metabolic syndrome have no symptoms.
Elevated triglycerides is high level of a certain type of fat (triglycerides) in the blood. Elevated triglycerides may contribute to pancreatitis or hardening of the arteries. This increases the risk of stroke, heart attack, and heart disease.

IPSCIO Record ID: 233152

License Grant
The Licensor grants to the Cayman Island Licensee and its Affiliates a sole and exclusive  royalty-bearing license, with the right to sublicense, under the Licensor IP and rights in the Product IP, to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize and have Commercialized Compounds and Products in the Field in the Territory.  The License provides exclusive rights to and use of the Licensors patent portfolio of Apo E mimetic peptides and formulations, which have anti-inflammatory properties, in the territory.
License Property
Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides.

Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease, and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral artery diseases.

Field of Use
Field means all diagnostic, therapeutic and prophylactic uses for all indications, except for the diseases of the eye.

IPSCIO Record ID: 121117

License Grant
The Swedish Licensee and the Licensor desire to establish a collaboration to apply such Licensor technology and expertise to the identification and characterization of biochemical pathways and targets in specific research areas relevant to metabolic syndrome and Alzheimers disease, and to provide for the development and commercialization of novel prophylactic and therapeutic products based on such research.

Licensor grants an exclusive, worldwide license under the Pre-existing Technologies and Sole Inventions Controlled by Licensor and under Licensors interest in the Joint Inventions to use each Selected Target to search for Collaboration Compounds directed at such Selected Target for activity within the Applicable Field, to develop, for use in the Applicable Field, Products comprising or incorporating such Collaboration Compounds, to develop, following, such Product for any human indication, and to make, have made, use, sell, offer to sell and have sold such Products.

License Property
The Pre-existing Technologies means any and all inventions, developments, results, know-how and other Information, and all intellectual property relating thereto, made, created or invented by a Party.

The Sole Inventions means any and all inventions, developments, results, know-how and other Information, and all intellectual property relating thereto, made, discovered or developed solely by a Party.

Homolog is a gene or gene product that has homology to a Selected Target.

Licensor is a biotechnology company that has expertise and proprietary technology relating to genetic model systems, genomics and computational biology and is applying such technology to discover and validate targets for drug discovery in a variety of disease areas, including metabolic syndrome and Alzheimers disease.

Field of Use
This agreement is for either the Field of Alzheimers Disease or the Field of Metabolic Syndrome.

Metabolic syndrome is a cluster of conditions — increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels — that occur together, increasing your risk of heart disease, stroke and diabetes.

Licensee is a multinational health care company that has expertise and capability in developing and marketing human pharmaceuticals and has research and development programs in the areas of, inter alia, metabolic syndrome and Alzheimers disease.

IPSCIO Record ID: 372528

License Grant
Licensor hereby grants to Licensee and its Affiliates, and Licensee hereby accepts on its and their behalf, a sole and exclusive license, with full rights to sublicense , under the Licensor Know-How, to (a) develop, use, sell, offer for sale, and import Licensed Products containing the Compound, Derivative or Additional Licensed Compound in the Field, in the Territory, and (b) make and have made Licensed Products in the Territory for such development, use, sale, offering for sale, and importation. Licensor hereby assigns to Licensee all of its rights, title and interest in and to the Licensor Patent Rights.
License Property
US Patent #7,317,125 – Diacylglycerol acyltransferase inhibitors

Licensed Product means any product containing a Compound, a Derivative or an Additional Licensed Compound, including all formulations, dosages, and dosage forms thereof.

Compound means the compound 4-(4-(4-[(2-phenyl-5-trifluoromethyloxazole-4-carbonyl)-amino]-phenyl)-piperidine-1-carbonyl)-cyclohexanecarboxylic acid, also known as RO5131723.

Field of Use
Field means all therapeutic, prophylactic, and other pharmaceutical uses and applications for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Metabolic syndrome is a cluster of conditions that occur together, increasing your risk of heart disease, stroke and type 2 diabetes. These conditions include increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels.

IPSCIO Record ID: 27002

License Grant
Licensor of Belgium hereby grants Licensee an exclusive, worldwide license under the Patent Rights and Know-How to develop, make, use, import, offer for sale and sell, and to have developed, made, used, imported, offered for sale and sold, the Licensed Products.  Licensee shall be entitled to grant sublicenses.
License Property
Compound means Pro-Apolipoprotein A-I.

Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part due to the accumulation of macrophage white blood cells and promoted by low density (especially small particle) lipoprotein (plasma proteins that carry cholesterol and triglycerides) without adequate removal of fats and cholesterol from the macrophages by functional high density lipoprotein (HDL), (see apoA-1 Milano).

Field of Use
Licensee, a company specialized in novel therapies for patients with atherosclerosis and related metabolic disorders, has an interest in acquiring exclusive rights to such patent rights, proprietary information and know-how with respect to the Compound.

IPSCIO Record ID: 301197

License Grant
Licensor grants the Licensee of Japan exclusive rights to NEXLETOL and NEXLIZET tablet development and commercialization in Japan.
License Property
NEXLETOL and NEXLIZE are cost-effective, oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicines.
Field of Use
The field of use is for hypercholesterolemia patients in Japan.  Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. It is a form of hyperlipidemia, high blood lipids, and hyperlipoproteinemia (elevated levels of lipoproteins in the blood).  High cholesterol can limit blood flow, increasing risk of heart attack or stroke.

IPSCIO Record ID: 4655

License Grant
The University hereby grants to Licensee an exclusive license to research, develop, make, have made, use, sell, offer for sale and import Licensed Products and to practice Licensed Methods in the Field of Use to the extent permitted by law. Licensee will not make, use, have made, sell, offer for sale, or import Licensed Products outside the Field of Use.
License Property
1. “Humanin and Humanin Analogues to treat T2DM ” (UCLA Case No. 2007-526)(U.S. Patent Application 12/451,524); and

2. “ Humanin and Humanin Analogues to treat T1DM” (UCLA Case No. 2007-714)(Issued US Patent 7,998,928 and U.S. Patent Application 13/180,181);

3. “SHLPs” (UCLA Case No. 2008-488)(U.S. Patent Application 12/989,688); and

4. “Humanin and analogues for atherosclerosis” (UCLA Case No. 2011-331)(U.S. Provisional Patent Application 61/498,474).

Licensed Product means any article, composition, apparatus, substance, chemical, or any other material covered by a Valid Claim within The University’s Patent Rights or whose manufacture, import use, offer for sale, or sale would, absent the license granted under this Agreement, constitute an infringement, inducement of infringement or contributory infringement of any Valid Claim within The University's Patent Rights, or any service, article, composition, apparatus, chemical, substance or any other material made, used or sold by or utilizing or practicing a Licensed Method. If the Licensed Product is a component of another product such as a kit, composition of matter or combination, such kit, composition of matter or combination is deemed to be the Licensed Product for purposes of this Agreement.

T2DM is Type 2 Diabetes Mellitus which is a chronic metabolic disease that affects the body’s ability to turn food into energy. Normally, after eating, sugar in the form of glucose from the food enters the bloodstream. The hormone Insulin, released from the pancreas in response to the rising levels of glucose in the bloodstream, is responsible for transporting the glucose into the body’s cells, to be used as fuel.

T1DM is Type 1 Diabetes Mellitus which is a chronic illness characterized by the body’s inability to produce insulin due to the autoimmune destruction of the beta cells in the pancreas. Onset most often occurs in childhood, but the disease can also develop in adults in their late 30s and early 40s.

Atherosclerosis is a disease in which plaque (plak) builds up inside your arteries. Arteries are blood vessels that carry oxygen-rich blood to your heart and other parts of your body. Plaque is made up of fat, cholesterol, calcium, and other substances found in the blood. Over time, plaque hardens and narrows your arteries. This limits the flow of oxygen-rich blood to your organs and other parts of your body. Atherosclerosis can lead to serious problems, including heart attack,stroke or even death.

Field of Use
Field of Use means all fields, including but not limited, to therapeutics and diagnostics.

IPSCIO Record ID: 294283

License Grant
Licensor grants to the Licensee of Japan an exclusive license in the Territory to use Licensor Know-how and the Licensed Compound to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell Licensed Product(s).

Licensor grants to an exclusive license in the Territory under the Patent Rights to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell the Licensed Compound, solely for use as an active ingredient in Licensed Products and Licensed Products.

License Property
Licensor has Know-How and the Patent Rights relating to the antidyslipidemic compound known as BT16.

BT/6 shall mean any form, including, without limitation, any salt, hydrate, crystalline structure or the like, of the small molecule compound identified by the chemical name B,B-tetramethyl hexadecane-a, (.)-dioic acid.

BT 2000 shall mean the compounds covered by PCT Patent W098/30530 including, without limitation, B, B -tetramethyloctadecanedioic acid.

Licensed Compound shall mean BT16.

The patents include Use of alpha, omega-dicarboxylic acids as fibrinogen sinkers, and, Pharmaceutical compositions containing carboxylic acids and derivatives thereof, and, Methods of administering 3,3,14,14 terramethyl hexadecane 1,16 dioic acid.

BT16 was found to have a potent efficacy of suppressing triglyceride levels in animal and human studies. Further studies demonstrated that it has also insulin-sensitizing properties and the possibility of this compound being developed as a metabolic syndrome therapy in the future has been suggested.

Field of Use
The phase II compound BT16 is r the treatment of dyslipidemia.

Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle.  Dyslipidemia increases the chance of clogged arteries (atherosclerosis) and heart attacks, stroke, or other circulatory concerns, especially in smokers.

Licensee possesses extensive capabilities in the development and commercialization of pharmaceutical products in Japan and in certain countries in Asia.  Licensor is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi interference or RNAi-based therapeutics.

IPSCIO Record ID: 5858

License Grant
The Licensor has granted the Licensee a non-revocable and exclusive worldwide license including the right to sublicense to third parties to the patents necessary to develop and commercialize drug candidates in which Cardio Vascu-Grow is the active ingredient. As a part of that agreement, Licensor will provide technical development services to us for the development and regulatory approvals of our drug candidates, including but not limited to, lab work, testing and production of our drug candidates in which Cardio Vascu-Grow is the active ingredient for clinical trials, all as directed by us.
License Property
We are working closely with an affiliated company, Cardio, pursuant to a joint patent and technology sharing agreement, to manufacture human fibroblast growth factor-1 (Cardio Vascu-Grow) for Cardio’s ongoing clinical trials.

Cardio Vascu-Grow Human Fibroblast Growth Factor-1 treat patients with advanced atherosclerotic disease of their coronary arteries. This treatment, which regenerates new blood vessels in the hearts of these patients.  Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part due to the accumulation of macrophage white blood cells and promoted by low density (especially small particle) lipoproteins (plasma proteins that carry cholesterol and triglycerides) without adequate removal of fats and cholesterol from the macrophages by functional high density lipoproteins (HDL), (see apoA-1 Milano).

Issued US Patents
1. U.S. 6,268,178 entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides;” and
2. U.S. 6,642,026 entitled “Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.”
3. U.S. 6,773,899 entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides”;
4. U.S. 6,794,162, entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides;”
Pending US Patent Applications 1.. U.S. 10/649,480 entitled “Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis;” published as US Patent Application No. US 2004/0115769

Field of Use
Cardio Vascu-Grow™ stimulates the growth of new blood vessels, a biological process termed “angiogenesis”. This growth factor is being tested in a wide variety of human diseases that would benefit from increased angiogenesis including coronary artery disease, stroke, and peripheral vascular disease of the legs and wound healing.

IPSCIO Record ID: 322362

License Grant
Licensor grants an exclusive, worldwide license to develop, manufacture and commercialize PCSK9.
License Property
PCSK9 is a RNAi therapeutics targeting proprotein convertase subtilisin/kexin type 9.

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that regulates low-density lipoprotein (LDL) receptor levels on hepatocytes; gain-of-function human mutations in PCSK9 are associated with hypercholesterolemia while loss-of-function mutations are associated with lower levels of LDL cholesterol and a reduced risk of cardiovascular disease.

Field of Use
PCSK9 is for the treatment of hypercholesterolemia and other human diseases, including inclisiran.

Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. It is a form of hyperlipidemia, high blood lipids, and hyperlipoproteinemia (elevated levels of lipoproteins in the blood).

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood which is known to increase the risk of coronary artery disease, the leading cause of death in the U.S. Some forms of hypercholesterolemia can be treated through dietary restrictions, lifestyle modifications (e.g., exercise and smoking cessation) and medicines such as statins.

Inclisiran is an experimental drug for the treatment of patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalents and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA that inhibits translation of the protein PCSK9.

IPSCIO Record ID: 291117

License Grant
The Canadian Licensor grants
—  an exclusive license for the Field in the Territory under the Licensed Patents; and
—  an exclusive license for the Field to use the Know-How in the Territory; for the sole and exclusive purpose of developing, making, having made, importing, using and selling Licensed Products in the Territory, including the right to grant sublicenses.
License Property
Licensed Products means human and veterinary therapeutic compositions and methods.

Licensed Patents are titled and related to Liposome Compositions and Methods for the Treatment of Atherosclerosis.

The European patents claim methods for treatment of atherosclerosis using liposomes. The U.S. patent applications claim liposome compositions and methods for treatment of disease, including atherosclerosis. The European patents expires in 2011.

Atherosclerosis refers to the buildup of fats, cholesterol and other substances in and on your artery walls (plaque), which can restrict blood flow. The plaque can burst, triggering a blood clot. Although atherosclerosis is often considered a heart problem, it can affect arteries anywhere in your body.

Field of Use
Together, the Basic Field, Improvements Field and Know-How Field comprise the Field.   Field means human and veterinary therapeutics, the Basic Field;
—  For Improvements, human and veterinary therapeutics, but limited to products that use or include Large Unilammelar Vesicles (LUVS) as a therapeutic agent which are not associated with any other therapeutic agent other than an apoprotein, the Improvements Field;
—  For Know-How, human and veterinary therapeutics, but limited to products that use or include Large Unilammelar Vesicles (LUVS) as a therapeutic agent which are not associated with any other therapeutic agent other than an apoprotein, the Know-How Field;

IPSCIO Record ID: 249743

License Grant
The German Licensor grants a non-transferable, exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Patent Rights and Know-How, to make, have made, use, sell, offer to sell, import, research, develop, commercialize and otherwise exploit Licensed Compounds and Licensed Products and Improvements. The foregoing license grant includes the right to make reference to all regulatory approvals, data, filings and correspondence, including DMFs contained within the Licensor Know-How.
License Property
Licensor has been engaged in the development of implitapide as an inhibitor of microsomal triglyceride transfer protein.

Licensed Compound means the compound known as Bay 13-9952 and identified as implitapide, and any metabolic precursors, prodrugs, isomers (chiral and otherwise), metabolites, hydrates, anhydrides, solvates, salt forms, free acids or bases, esters, amides, ethers, complexes, conjugates or polymorphs of any compounds.

Field of Use
Licensee is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders.

Lipid disorder means a high blood levels of low-density lipoprotein (LDL) cholesterol, fats called triglycerides, or both.  Lipid disorders, such as high cholesterol, can increase the risk of heart problems, such as heart attack.

IPSCIO Record ID: 368502

License Grant
The Licensor grants to the Licensee of Russia a nonexclusive right and license, with the right to sublicense, under the Licensed Technology to conduct applicable clinical or related scientific trials for the registration of Licensed Compounds and/or Licensed Products in the Field and the Territory; and an exclusive right and license, with the right to sublicense, to use the Licensed Technology only for applications within the Field and in the Territory, including the rights to import, transfer, use, offer for sale and sell Licensed Compounds and/or Licensed Products in the Territory.
License Property
Licensor owns certain technology and patent rights regarding AHRO-001, an investigational drug candidate for the treatment of dyslipidemia and regression of atherosclerotic plaque.

Licensed Compounds shall mean AHRO-001 including all stereoisomers, polymorphs, prodrugs, analogs, active metabolites and salts of any of the foregoing further including any and all related backup compounds and analogs disclosed and claimed in the Licensor Patent Rights which are subsequently substituted for AHRO-001.

The patents include Dissolution of Arterial Plaque, and, Compositions and Methods for Treating Obesity.

Field of Use
AHRO-001 is in phase I clinical trials for the treatment of atherosclerosis.

Arteriosclerosis is the thickening, hardening, and loss of elasticity of the walls of arteries.  This process gradually restricts the blood flow to one's organs and tissues and can lead to severe health risks brought on by atherosclerosis, which is a specific form of arteriosclerosis caused by the buildup of fatty plaques, cholesterol, and some other substances in and on the artery walls.

The Field shall mean all human diagnostic and therapeutic applications of the Licensed Technology disclosed in the Licensor Patent Rights including without limitation the treatment of Dyslipidemia and the regression of atherosclerotic plaque.

IPSCIO Record ID: 291116

License Grant
The Inventors grant the Company
—  an exclusive, worldwide license, with the right to grant sublicenses, under the Licensed Patents to make, have made, use, import, offer for sale, sell and otherwise dispose of the Licensed Products in the Field, and
—  subject to any pre-existing rights of third Persons, a non-exclusive worldwide license, with the right to grant sublicenses, under the Know-How to make, have made, use, import, offer for sale, sell and otherwise dispose of the Licensed Products in the Field.
License Property
The know-how and property is for compositions and uses of peptide mimetics of Apoprotein A-I.  The patent is for Apolipoprotein A-1 Agonists and their use to treat dyslipidemic disorders.
Field of Use
The Field means Apoprotein A-I mimetics as described in the Licensed Patents for the diagnosis and/or treatment of atherosclerosis and related metabolic diseases.

Arteriosclerosis is the thickening, hardening, and loss of elasticity of the walls of arteries.  Atherosclerosis is the primary cause of coronary artery disease (CAD) and stroke, with multiple genetic and environmental contributions.

IPSCIO Record ID: 7419

License Grant
The Licensee, as part of a strategic alliance, entered into an agreement with the Belgium Licensor.

The Licensor granted the Licensee an exclusive, worldwide, royalty-bearing license to MBX-8025 and certain other PPAR compounds (the PPAR Products) with the right to grant sublicenses to third parties to make, use and sell such PPAR Products.

License Property
PPAR – Peroxisome proliferator-activated receptors form a family of nuclear hormone receptors involved in energy hemostasis and lipid metabolism.

MBX-8025 is a selective agonist (a substance that stimulates a response by binding to a receptor) for the peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes involved in lipid storage and transport (particularly in fatty acid oxidation) and insulin signaling and sensitivity. In preclinical studies in rodents, dogs and primates, MBX-8025 demonstrated a variety of beneficial effects on the lipid profile and other metabolic parameters. MBX-8025 treatment increased peripheral oxidation of fatty acids leading to reduced levels of triglycerides (TGs) and low-density lipoprotein (LDL), while raising high-density lipoprotein (HDL). MBX-8025 inhibited fat mass accumulation, resulting in attenuation of body weight gain in rodent models of obesity.

MBX-8025 has potential therapeutic application for disorders linked to deficits in lipid storage, handling and utilization, many of which result in metabolic disorders. To date, it has been in development as a first-in-class treatment that effectively addresses all three lipid disorders associated with mixed dyslipidemia (abnormal lipid levels in the blood) as well as a majority of the cardiovascular risk factors that define metabolic syndrome. The future development program will focus on high unmet need indications in dyslipidemia as well as in high unmet need specialty and orphan diseases.

The 8-week Phase 2 study investigated MBX-8025 at doses of 50 or 100 mg/day in moderately obese patients with mixed dyslipidemia. The study demonstrated that treatment with MBX-8025 led to significant reductions in total LDL (~20%) and selective depletion of the small dense atherogenic (promotion of arterial plaque formation) LDL particles, resulting in an exceptional improvement in the LDL particle size profile. It also decreased TGs (~30%) and raised HDL (~12%). This unique combination of effects significantly decreased the atherogenic risk of patients’ lipid profile. When administered in combination with atorvastatin (Lipitor®), MBX-8025 provided a comprehensive improvement in all lipid and cardiovascular risk parameters without side effects seen in other combination lipid therapies.

In addition, MBX-8025 addressed other aspects of metabolic syndrome, including improvements in insulin sensitivity and trends toward decreased waist circumference and body fat. Over half of the patients that entered the Phase 2 study meeting the criteria for metabolic syndrome no longer met the criteria at the end of the study.

The product seladelpar is for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver. Seladelpar is a potent and selective agonist of PPARd, a nuclear receptor that regulates genes important for lipid, bile acid/sterol and glucose metabolism and for inflammation in liver and muscle.

Field of Use
This agreement pertains to the drug industry relating to treatment of an autoimmune disease.

Under the terms of the agreement, the Licensee has full control and responsibility over the research, development and registration of any PPAR Products and is required to use diligent efforts to conduct all such activities.

The Licensee shall grant the Licensor a worldwide, exclusive, irrevocable license under the agreement in all information that is controlled, developed or acquired by the Licensee which relates to a PPAR compound or PPAR product and in all patents that are filed.

IPSCIO Record ID: 368507

License Grant
The Licensor, an individual, hereby grants to Licensee an exclusive license to practice under the Licensed Patents and use the licensed information, with the right to grant sublicenses, to make, have made, use, sell, have sold, offer to sell, import or export Licensed Products within the field in the licensed territory (the License).
License Property
The intellectual property portfolio for 2NTX-99 includes an issued U.S. patent and a pending Patent Cooperative Treaty submission relating to its composition of matter, multiple methods of manufacturing, and method of use in treating a variety of atheroclerotic-thrombotic pathological conditions.

U.S. Patent 6,525,078 B1 dated February 24, 2003 entitled “Compound for the Treatment of Athreosclerotic-Thrombotic Pathological Conditions.

Field of Use
2NTX-99 has potential utility in a range of atherosclerotic, thrombotic and microvascular diseases.

Atherosclerosis is thickening or hardening of the arteries caused by a buildup of plaque in the inner lining of an artery.
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system. Blood clotting, also known as coagulation, is the body's first line of defense against bleeding.
Coronary disease (MCD) is the narrowing of the small blood vessels that branch off the coronary arteries and send oxygen-rich blood to the heart muscle. This decreases the amount of blood that goes to the heart muscle, which leads to chest pain (angina).

IPSCIO Record ID: 279309

License Grant
Licensor grants to the Licensee of Puerto Rico an exclusive license, with the right to sublicense, under the Licensor Compound Patents, Other Licensor Patents and Licensor Know-How, to research, develop, make, have made, use, sell, have sold, offer for sale and import the Compound and Products in the Field in the Territory.

Licensor grants a non-exclusive, royalty free license to use Licensors corporate Trademarks solely for purposes of Commercializing Products, which license shall terminate upon the expiration or earlier termination of this Agreement for any reason.

License Property
Licensor is engaged in manufacturing, research and development of pharmaceutical products and is currently engaged in the development of AGI-1067.  

Compound means AGI-1067, which is chemically defined as Butanedioic acid, including its pharmacologically acceptable salts, solvates, hydrates, hemihydrates, polymorphs, metabolites; free base forms, pro-drugs, esters, tautomers and if applicable, any isomers, stereoisomers, racemates, enantiomers and all optically active forms thereof.

AGI-1067 is a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.

Field of Use
Licensee is engaged in the research, development, manufacture and marketing of pharmaceutical products.  AGI-1067 is designed to benefit patients with coronary heart disease (CHD), which is atherosclerosis of the blood vessels of the heart.   Atherosclerosis is a common disease that results from inflammation and the buildup of plaque in arterial blood vessel walls.

IPSCIO Record ID: 281186

License Grant
The Japanese Licensor hereby grants and agrees to grant to Licensee (i) an exclusive (except as to Licensor), royalty-bearing license (with the right to sublicense) under the Program Patents, Program Know-How, and the Licensor Technology to the extent necessary develop, have developed (following approval of the MC in accordance with this agreement), make, have made, use, import, offer for sale, sell and have sold (following approval of the MC in accordance with this agreement) any Product in the Co-Promotion Territory; and (ii) an exclusive (even as to Licensor), royalty-bearing license (with the right to sublicense) under the Program Patents, Program Know-How, and the Licensor Technology to develop, have developed, make, have made, use, import, offer for sale, sell and have sold (with the right to sublicense) any Product in the Licensee Territory.
License Property
Product shall have the meaning regarding Lead Compound and Research Compound. Products do not include Independent Products.

Lead Compound shall mean a Substance designated by the RMC as suitable for initial development against a Current Program Target within the Field based upon results of screening performed pursuant to this agreement.  Lead Compounds may be selected as Collaboration Lead Compounds.

Research Compound shall mean any compound that is based upon a Substance that agonizes or antagonizes a Current Program Target and that is made, created, discovered, identified, invented, synthesized, optimized or acquired by or on behalf of either Party pursuant to the Research Plan, or otherwise in the course of the Program. Research Compounds may be selected as Collaboration Lead Compounds.

Program Patents shall mean patents and patent applications, both foreign and domestic, including without limitation all substitutions, provisionals, continuations, continuations-in-part, divisionals, extensions, reexaminations, reissues, renewals, supplementary protection certificates and inventors certificates, that are owned or controlled by either Party or both Parties and claim Program Inventions made during the Term in the course of the discovery, research, Pre-Clinical Development, Development and commercialization of Substances, Lead Compounds, Research Compounds, Collaboration Lead Compounds, Independent Lead Compounds, Products or Independent Products pursuant to the Program. Program Patents shall exclude Research Compound Patents and Program Know-How.

Licensor Technology shall mean, collectively, the Patent Rights and the Know-How owned or controlled by Licensor.

RMC shall mean the research management committee.

MC shall mean the marketing committee.

Field of Use
Field shall mean the agonism or antagonism of Current Program Targets for the treatment of disease in humans.

The deal is for the discovery, development and commercialization of products to treat metabolic diseases.  Metabolic syndrome is a cluster of conditions that occur together, increasing your risk of heart disease, stroke and type 2 diabetes. These conditions include increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels.

This collaboration agreement is to research and develop orphan nuclear receptor agonists and antagonists.

IPSCIO Record ID: 25782

License Grant
The University has an assignment of an invention describing approaches to identify novel candidate genes implicated in the development of atherosclerosis, which represent likely targets for future novel diagnostic and therapeutic strategies and the University grants the Licensee an exclusive worldwide license under the Licensed Patent in the exclusive licensed Field of Use to make, have made, use, offer for sale, sell, import, Licensed Product and practice any method or procedures and to have any of the foregoing performed on its behalf by a third party in the Licensed territory including the right to subLicense.
License Property
Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part due to the accumulation of macrophage white blood cells and promoted by low density (especially small particle) lipoproteins (plasma proteins that carry cholesterol and triglycerides) without adequate removal of fats and cholesterol from the macrophages by functional high density lipoproteins (HDL), (see apoA-1 Milano). It is commonly referred to as a hardening or furring of the arteries. It is caused by the formation of multiple plaques within the arteries.
Field of Use
Term Limited Field Of Use means any and all nontherapeutic applications such as diagnostic use and research reagents.

IPSCIO Record ID: 372642

License Grant
Licensor, a nonprofit academic medical center, hereby grants to Licensee for the Term an exclusive, worldwide license to use the Licensed Technology in the Field of Use to (i) make, have made, develop, use, import, export, distribute, market, promote, offer for sale, and sell Products in the Field of Use, and (ii) practice in the Field of Use any method, process or procedure claimed within the Licensed Technology.
License Property
Licensed Patents
– U.S. Utility Application No.11/700,987, Filed 2/1/2007, “A METHOD AND APPARATUS FOR INCREASING BLOOD FLOW THROUGH AN OBSTRUCTED BLOOD VESSEL”, Henry Woo, MD, David Fiorella, MD, PhD. Publication Number US 20070208361 A1.

– U.S. Application No.60/764,206, Filed 2/1/2006, “A METHOD AND APPARATUS FOR INCREASING BLOOD FLOW THROUGH AN OBSTRUCTED BLOOD VESSEL”, Henry Woo, MD, David Fiorella, MD, PhD. Expired.

-U.S. Application No.60/793,588, Filed 4/20/2006, “A METHOD AND APPARATUS FOR INCREASING BLOOD FLOW THROUGH AN OBSTRUCTED BLOOD VESSEL”, Henry Woo, MD, David Fiorella, MD, PhD. Expired.

Field of Use
The license relates to its revascularization technology for the treatment of ischemic stroke.

Ischemic stroke occurs when a blood clot blocks or narrows an artery leading to the brain. A blood clot often forms in arteries damaged by the buildup of plaques (atherosclerosis). It can occur in the carotid artery of the neck as well as other arteries. This is the most common type of stroke.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.